Summit Therapeutics (SMMT) announced Tuesday morning that it has entered into an exclusive license and collaboration agreement with Sarepta Therapeutics (SRPT). The agreement grants Sarepta rights in Europe, Turkey and the Commonwealth of Independent States to Summit's utrophin modulator pipeline.
from RTT - Hot Stocks http://ift.tt/2dO8VEQ
via IFTTT
No comments:
Post a Comment